Multiple Sclerosis Journal最新文献_第9页

Reply to letter: "On observing the standards of descriptive epidemiology: Comment on the article by Ozturk et al." by author Koray Tascilar MD. 回复：“关于观察描述性流行病学的标准：对Ozturk等人的文章的评论”，作者Koray Tascilar医学博士。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2024-12-31 DOI: 10.1177/13524585241306651

Bilgin Öztürk, Murat Kürtüncü

引用次数: 0

Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study. 前驱期多发性硬化症的分娩率降低：来自人群队列研究的证据。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-02-17 DOI: 10.1177/13524585251315077

Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, Kamilla Brekke, Harald Myklebust, Pål Berg-Hansen, Cathrine Brunborg, Elisabeth Gulowsen Celius

{"title":"Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.","authors":"Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, Kamilla Brekke, Harald Myklebust, Pål Berg-Hansen, Cathrine Brunborg, Elisabeth Gulowsen Celius","doi":"10.1177/13524585251315077","DOIUrl":"10.1177/13524585251315077","url":null,"abstract":"Background: The age of multiple sclerosis (MS) onset coincides with fertile age, and both improved prognosis and treatment may influence birth rates in people with MS (pwMS).Objectives: To investigate birth rates over time in pwMS compared with controls.Methods: This cohort study included pwMS from three hospitals in the southeast of Norway. Clinical data were collected prospectively. Statistics Norway provided year of live births and marital status in pwMS and controls matched for age, sex, and place of residence at age 16.Results: We included 1599 pwMS (1118 women with MS (wMS) and 481 men with MS (mMS)) and 23,855 controls. The mean number of live births was 1.5 (standard deviation (SD) 1.2) for pwMS versus 1.8 (SD 1.2) for controls (p < 0.001). Birth rates in wMS declined significantly starting 3 years before onset, with 4.5% giving birth versus 8.4% of controls 2 years before onset (p = 0.046). Birth rates were also lower 1 year after onset (p = 0.002). mMS showed a dip 2 years before onset (p = 0.002), but otherwise had rates similar to controls. There were no differences in marital status.Conclusion: wMS have reduced rates of childbirth compared with controls. This is significant already in the prodromal phase.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"398-407"},"PeriodicalIF":4.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis. 神经状态- smartcare临床试验：使医疗保健专业人员能够评估多发性硬化症分散试验中的EDSS。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI: 10.1177/13524585241305966

Giulia Mallucci, Andrea Zimmer, Nikolaos Sfikas, Nuria Cerdá-Fuertes, Simon Wunderlin, Ioanna Athanasopoulou, Magdalena Mroczek, Vanny Phavanh, Lisa Sanak, Jolanda Suter, Bernadette Friedli, Jakob Kel, Thomas Trouillet, Sarah Simmen, Alex Ocampo, Wenjia Wei, Bernd Kieseier, Christian P Kamm, Ludwig Kappos, Marcus D'Souza

{"title":"Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.","authors":"Giulia Mallucci, Andrea Zimmer, Nikolaos Sfikas, Nuria Cerdá-Fuertes, Simon Wunderlin, Ioanna Athanasopoulou, Magdalena Mroczek, Vanny Phavanh, Lisa Sanak, Jolanda Suter, Bernadette Friedli, Jakob Kel, Thomas Trouillet, Sarah Simmen, Alex Ocampo, Wenjia Wei, Bernd Kieseier, Christian P Kamm, Ludwig Kappos, Marcus D'Souza","doi":"10.1177/13524585241305966","DOIUrl":"10.1177/13524585241305966","url":null,"abstract":"Background: Neurostatus-Expanded Disability Status Scale (EDSS) is the standard measure used to assess impairment and disability in multiple sclerosis (MS) trials but requires trained expert neurologists.Objectives: This study aims to evaluate the concordance of Neurostatus-EDSS assessments from specially trained health care professionals (HCPs) and standardized trained neurologists.Methods: A Swiss multicenter, randomized, cross-over study with 100 people with MS. HCPs were trained to assess the Neurostatus-EDSS based on the newly developed SMARTCARE-EDSS training method.Results: The concordance rate between HCPs and neurologists was 0.87 (95% confidence interval (CI) = 0.815-0.925).Conclusion: Trained HCPs can reliably perform Neurostatus-EDSS assessments, supporting broader implementation and improved trial access.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"497-501"},"PeriodicalIF":4.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort. 多发性硬化症病程中的三叉神经痛：来自多中心队列的诊断和治疗意义。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2024-12-27 DOI: 10.1177/13524585241309257

Sini M Laakso, Jiwon Oh, Fasna Raufdeen, Ashley Jones, Henri Reiskanen, Ken Feb, Elle Levit, Andrew J Solomon

引用次数: 0

Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies. 治疗反应评分系统在接受高效治疗的多发性硬化症患者中的表现

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-02-10 DOI: 10.1177/13524585251316471

Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia

{"title":"Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.","authors":"Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia","doi":"10.1177/13524585251316471","DOIUrl":"10.1177/13524585251316471","url":null,"abstract":"Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and very high-efficacy therapies (HET/vHET) remains unclear.Objective: This study aimed to evaluate the performance of TRSS in patients treated with HET/vHET.Methods: We retrospectively studied MS patients treated with HET/vHET in an MS specialized centre. TRSS, including the Rio Score, modified Rio Score and MAGNIMS score, were applied to assess response to treatment. We evaluated the predictive value of the TRSS on disease activity and disability progression.Results: TRSS effectively predicted disease activity and progression of disability in patients treated with HET/vHET. Patients with high TRSS scores at 12 months post-HET/vHET initiation had a significantly increased risk of relapses, new lesions on magnetic resonance imaging (MRI) scans and progression of disability at 4 years.Discussion: Our findings highlight the importance of personalized treatment strategies in MS. TRSS are valuable tools for monitoring treatment response, guiding clinical decision-making and optimizing patient care.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"568-577"},"PeriodicalIF":4.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

We need to engage representative patients' community rather than 'expert patients' to increase impact of research in the era of personalised medicine: Yes. 我们需要让有代表性的患者社区而不是“专家患者”参与进来，以增加个性化医疗时代研究的影响。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-02-11 DOI: 10.1177/13524585251315338

Usman Khan

引用次数: 0

Acute eculizumab treatment in a pediatric patient with AQP4-IgG+ NMOSD. 急性依珠单抗治疗AQP4-IgG+ NMOSD患儿

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-01-22 DOI: 10.1177/13524585241283650

Ria H Soni, Mekka Garcia, Eunhye Oak, Eliana J Applbaum, Logi Rajagopalan, Lauren B Krupp, Kimberly A O'Neill

引用次数: 0

Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients. 有氧能力调节轻度残疾多发性硬化症患者颈髓萎缩与临床残疾之间的关系。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-02-14 DOI: 10.1177/13524585251318647

Matteo Albergoni, Paolo Preziosa, Alessandro Meani, Chiara Dallari, Paola Valsasina, Maria A Rocca, Massimo Filippi

{"title":"Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients.","authors":"Matteo Albergoni, Paolo Preziosa, Alessandro Meani, Chiara Dallari, Paola Valsasina, Maria A Rocca, Massimo Filippi","doi":"10.1177/13524585251318647","DOIUrl":"10.1177/13524585251318647","url":null,"abstract":"Background: Spinal cord volume loss is associated with clinical disability in multiple sclerosis (MS). Aerobic capacity may mitigate the impact of central nervous system (CNS) damage accumulation, exerting beneficial effects on MS-related disability.Objectives: We investigated whether aerobic capacity could moderate the association between spinal cord atrophy and clinical disability in MS.Methods: In this cross-sectional analysis, expanded disability status scale (EDSS), peak of oxygen consumption (VO2peak), brain volumetric measures, and the normalized mean upper cervical cord area (nMUCCA) were collected from 51 MS patients and 33 healthy controls (HCs). Low aerobic capacity was defined as having a VO2peak z-score less than -1.64 standard deviations. In MS patients, we explored whether the association between nMUCCA and EDSS is moderated by the level of aerobic capacity.Results: The relationship between nMUCCA and EDSS was moderated by aerobic capacity, with a significant nMUCCA × aerobic capacity interaction (β = -0.099, 95% bootstrapped confidence interval [CI] = [-0.172; -0.014], p = 0.012). Lower nMUCCA was significantly associated with higher EDSS score in MS patients with low aerobic capacity (β = -0.073, p < 0.001), but not in those with high aerobic capacity (β = 0.026, p = 0.417).Conclusions: In MS patients with mild disability, higher aerobic capacity can potentially mitigate the negative impact of spinal cord damage on clinical disability.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"558-567"},"PeriodicalIF":4.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis. ocrelizumab在智利多发性硬化症患者中的实际应用证据。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-01-06 DOI: 10.1177/13524585241309835

Adolfo Del Canto, Claudia Cárcamo, Lorena Garcia, Ester Aylwin, Lukas Jürgensen-Heinrich, Ignacio Guzman-Carcamo, Juan de la Barra, Leticia Gutierrez-Calquin, Antonia Barrera-Hormazabal, Juan Pablo Cruz, Sebastián Bravo, Carolina Pelayo, Bernardita Soler, Reinaldo Uribe-San-Martin, Ethel Ciampi

{"title":"Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.","authors":"Adolfo Del Canto, Claudia Cárcamo, Lorena Garcia, Ester Aylwin, Lukas Jürgensen-Heinrich, Ignacio Guzman-Carcamo, Juan de la Barra, Leticia Gutierrez-Calquin, Antonia Barrera-Hormazabal, Juan Pablo Cruz, Sebastián Bravo, Carolina Pelayo, Bernardita Soler, Reinaldo Uribe-San-Martin, Ethel Ciampi","doi":"10.1177/13524585241309835","DOIUrl":"10.1177/13524585241309835","url":null,"abstract":"Background: Real-world studies are needed to expand our knowledge concerning populations underrepresented in clinical trials.Objective: This study aimed to evaluate the safety and effectiveness of ocrelizumab in Hispanic/Latino people with multiple sclerosis (pwMS).Methods: Prospective longitudinal observational study including pwMS who received at least one dose of ocrelizumab between June 2018 and October 2023.Results: A total of 305 pwMS (223 relapsing-remitting MS (RRMS), 29 secondary progressive MS (SPMS), and 53 primary progressive MS (PPMS)), 67% female, mean age 38.7, mean disease duration 7 years, and median Expanded Disability Status Scale (EDSS) 2.0 (range 0-7). Median follow-up under ocrelizumab 29.5 (range 6-65) months. Only 1 patient had a relapse, 12-week-confirmed disability worsening was observed in 12.4% of the full cohort. Survival analysis showed higher risk of 12-week-confirmed disability worsening in SPMS compared with RRMS and PPMS (p = 0.0009). Magnetic resonance imaging (MRI) activity was significantly reduced from baseline across all disease phenotypes. Serious infections were observed in 4.6%, and two patients died during follow-up (one serious COVID-19 and one metastatic cancer). Notably, 22 pregnancies were reported, with 11 newborns and 6 pregnancies still on course.Conclusion: This study supports the effectiveness of ocrelizumab in a real-world cohort of individuals from traditionally underrepresented groups, such as the Latin American population, with a consistent safety profile in patients receiving care at a specialized MS Unit.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"444-454"},"PeriodicalIF":4.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives. confavreux讲座：影像学孤立综合征的诊断、预后及展望。

IF 4.8 2区医学

Multiple Sclerosis Journal Pub Date : 2025-03-01 Epub Date: 2025-01-17 DOI: 10.1177/13524585241311217

Christine Lebrun-Frenay

{"title":"The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives.","authors":"Christine Lebrun-Frenay","doi":"10.1177/13524585241311217","DOIUrl":"10.1177/13524585241311217","url":null,"abstract":"Radiologically isolated syndrome (RIS) is the earliest documented stage in the disease continuum of multiple sclerosis (MS). It is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain or spinal cord suggestive of autoimmune inflammatory demyelination. The revised 2023 RIS criteria aim to secure an accurate and timely diagnosis due to the presence of imaging mimics. These criteria require having at least one T2-weighted hyperintense lesion in one of the four suggestive MS locations along with two of the following three features: spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, or new T2 or gadolinium-enhancing lesion observed on a subsequent magnetic resonance imaging (MRI) study. Once the diagnosis is confirmed, established risk factors, including age, lesion location and CSF, significantly improve prognostic stratification, which is crucial for immunoactive interventions. Recent clinical trials have shown that oral disease-modifying treatments can delay or prevent the first clinical event in RIS patients. Consulting with an MS team for each RIS case is strongly recommended to enhance care and disease surveillance. The revised 2024 McDonald criteria will classify individuals with additional CSF and advanced MRI biomarkers as having preclinical MS, highlighting the importance of vigilance in this area.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"249-256"},"PeriodicalIF":4.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0